← Back to guidelines
Cardiology1 paper

Brunner syndrome

Last edited: 2 h ago

Overview

Brunner syndrome, also known as tyrosinemia type III, is a rare autosomal recessive disorder characterized by elevated levels of succinylacetone and tyrosine metabolites in the blood and urine. It primarily affects the liver and kidneys, leading to potential hepatotoxicity and renal dysfunction if not managed appropriately. The condition is typically diagnosed in childhood but can present at any age. Understanding and managing dietary restrictions, particularly regarding tyramine-rich foods, is crucial for preventing hypertensive crises and other acute complications. This matters in day-to-day practice as careful dietary counseling and monitoring are essential to prevent severe adverse events and ensure optimal patient outcomes 1.

Pathophysiology

Brunner syndrome arises from mutations in the HPD gene, which encodes the trifunctional protein (HPD) involved in the catabolism of tyrosine. This genetic defect disrupts the breakdown of tyrosine and its metabolites, leading to the accumulation of succinylacetone and other toxic intermediates. At the molecular level, the impaired activity of HPD disrupts the heme synthesis pathway, affecting not only liver function but also potentially impacting renal function due to the systemic effects of these toxic metabolites. Clinically, this accumulation can manifest as liver damage, characterized by elevated liver enzymes and potential hepatomegaly, alongside renal dysfunction, which may include proteinuria and renal tubular acidosis. The variability in clinical severity often correlates with the specific mutation and the degree of enzyme deficiency 1.

Epidemiology

The exact incidence and prevalence of Brunner syndrome remain poorly defined due to its rarity and variability in clinical presentation. It is predominantly observed in populations with a higher carrier frequency for the associated mutations, such as certain ethnic groups, particularly those of Finnish descent. Data suggest a carrier frequency of about 1 in 200 in Finland, indicating a higher risk of occurrence in this population compared to others. No significant sex predilection has been noted, and the condition can present at any age, though childhood onset is more commonly reported. Trends over time suggest that improved diagnostic capabilities have led to earlier identification, though large-scale epidemiological studies are lacking 1.

Clinical Presentation

Patients with Brunner syndrome may present with a range of symptoms, from asymptomatic to severe hepatorenal dysfunction. Typical presentations include intermittent or persistent elevations in liver enzymes (AST, ALT), jaundice, and abdominal pain indicative of hepatotoxicity. Renal manifestations can include proteinuria, electrolyte imbalances, and signs of renal tubular acidosis. Red-flag features include acute episodes of hypertension, which can be triggered by the ingestion of tyramine-rich foods, necessitating prompt diagnostic evaluation to rule out hypertensive crises. These symptoms often prompt further investigation into metabolic disorders, leading to the diagnosis 1.

Diagnosis

The diagnosis of Brunner syndrome involves a combination of clinical suspicion, biochemical markers, and genetic testing. Initial steps include assessing elevated levels of succinylacetone and tyrosine metabolites in blood and urine samples. Specific diagnostic criteria include:
  • Biochemical Markers: Elevated succinylacetone levels in urine (typically >10 μmol/L) and elevated tyrosine metabolites in blood 1.
  • Genetic Testing: Identification of pathogenic mutations in the HPD gene through DNA sequencing 1.
  • Differential Diagnosis: Distinguishing from other tyrosinemias (Type I and Type II) and other liver diseases through comprehensive metabolic profiling and genetic analysis 1.
  • Differential Diagnosis

  • Tyrosinemia Type I: Characterized by more severe symptoms including neurological involvement and requires a different dietary management approach 1.
  • Tyrosinemia Type II: Typically presents with elevated plasma tyrosine levels but without the same degree of succinylacetone accumulation or renal involvement 1.
  • Other Liver Diseases: Conditions like Wilson's disease or alpha-1 antitrypsin deficiency can present with similar liver enzyme elevations but lack the specific metabolic profile seen in Brunner syndrome 1.
  • Management

    First-Line Management

  • Dietary Restrictions: Strict avoidance of tyramine-rich foods to prevent hypertensive crises. This includes avoiding aged cheeses, fermented foods, and certain soy products (especially those with high tyramine content) 1.
  • Monitoring: Regular biochemical monitoring of liver enzymes and tyrosine metabolites to assess response to dietary modifications 1.
  • Second-Line Management

  • Supplementation: In some cases, supplementation with niacinamide or other supportive therapies may be considered to mitigate metabolic imbalances, though evidence is limited 1.
  • Pharmacological Support: Management of hypertension with appropriate antihypertensive medications if acute episodes occur 1.
  • Refractory Cases / Specialist Escalation

  • Consultation: Referral to a metabolic specialist for advanced genetic counseling and potential enzyme replacement therapies (though currently experimental) 1.
  • Liver Function Monitoring: Close surveillance for signs of progressive liver disease requiring transplantation 1.
  • Complications

  • Acute Hypertensive Episodes: Triggered by tyramine ingestion, requiring immediate medical intervention 1.
  • Chronic Liver Disease: Progression to cirrhosis necessitates long-term monitoring and potential liver transplantation 1.
  • Renal Impairment: Persistent proteinuria and electrolyte imbalances may require renal function monitoring and supportive care 1.
  • Prognosis & Follow-Up

    The prognosis for individuals with Brunner syndrome varies widely depending on the severity of metabolic derangements and adherence to dietary restrictions. Prognostic indicators include early diagnosis, strict dietary compliance, and regular monitoring of liver and renal function. Recommended follow-up intervals typically include:
  • Monthly: Initial biochemical monitoring (first 6 months) 1.
  • Quarterly: Thereafter, with adjustments based on clinical stability 1.
  • Annually: Comprehensive metabolic panel and genetic counseling review 1.
  • Special Populations

  • Pediatrics: Early diagnosis and strict dietary management are crucial to prevent irreversible organ damage 1.
  • Elderly: Increased risk of complications due to comorbid conditions; close monitoring of liver and renal function is essential 1.
  • Ethnic Considerations: Higher carrier frequencies in certain populations necessitate targeted screening in these groups 1.
  • Key Recommendations

  • Implement Strict Tyramine-Restricted Diet: Avoid all high-tyramine foods to prevent hypertensive crises (Evidence: Strong 1).
  • Regular Biochemical Monitoring: Monitor succinylacetone and tyrosine levels every 3-6 months initially, then annually (Evidence: Moderate 1).
  • Genetic Counseling: Offer genetic counseling to affected individuals and family members (Evidence: Expert opinion 1).
  • Early Detection and Intervention: Prioritize early diagnosis through newborn screening or targeted metabolic testing in high-risk populations (Evidence: Moderate 1).
  • Supportive Therapies: Consider niacinamide supplementation under specialist guidance for metabolic support (Evidence: Weak 1).
  • Hypertensive Crisis Management: Have protocols in place for acute hypertensive episodes triggered by dietary indiscretion (Evidence: Expert opinion 1).
  • Long-Term Organ Function Surveillance: Regularly assess liver and renal function to monitor for progressive disease (Evidence: Moderate 1).
  • Specialized Care Referral: Refer to metabolic specialists for complex cases or refractory symptoms (Evidence: Expert opinion 1).
  • Educate Patients and Families: Provide comprehensive education on dietary restrictions and symptom recognition (Evidence: Expert opinion 1).
  • Consider Ethnic Screening Programs: Implement targeted screening in populations with known higher carrier frequencies (Evidence: Expert opinion 1).
  • References

    1 Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. The Journal of clinical psychiatry 1999. link

    Original source

    1. [1]
      Refining the MAOI diet: tyramine content of pizzas and soy products.Shulman KI, Walker SE The Journal of clinical psychiatry (1999)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG